CTMX - CytomX Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

CTMX is currently covered by 7 analysts with an average price target of $6.55. This is a potential upside of $4.45 (211.9%) from yesterday's end of day stock price of $2.1.

CytomX Therapeutics's activity chart (see below) currently has 71 price targets and 69 ratings on display. The stock rating distribution of CTMX is 55.56% HOLD and 44.44% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 30.57% with an average time for these price targets to be met of 103 days.

Highest price target for CTMX is $5, Lowest price target is $2.5, average price target is $5.34.

Most recent stock forecast was given by MITCHELL KAPOOR from HC WAINWRIGHT on 20-May-2025.

Currently out of the existing stock ratings of CTMX, 10 are a HOLD (55.56%), 8 are a BUY (44.44%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$5

$2.9 (138.10%)

$5

2 months 21 days ago
(20-May-2025)

0/2 (0%)

$2.94 (142.72%)

Buy

$5

$2.9 (138.10%)

$2.5

2 months 26 days ago
(15-May-2025)

3/8 (37.5%)

$3 (150.00%)

49

Buy

$2.5

$0.4 (19.05%)

3 months 27 days ago
(14-Apr-2025)

2/4 (50%)

$1.89 (309.84%)

27

Hold

$3.56

$1.46 (69.52%)

$3.59

1 years 1 days ago
(09-Aug-2024)

8/14 (57.14%)

$2.36 (196.67%)

258

Buy

$8

$5.9 (280.95%)

$3

1 years 3 months 1 days ago
(09-May-2024)

4/9 (44.44%)

$5.96 (292.16%)

133

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is CTMX (CytomX Therapeutics) average time for price targets to be met?

On average it took 103 days on average for the stock forecasts to be realized with a an average price target met ratio 30.57

Which analyst has the current highest performing score on CTMX (CytomX Therapeutics) with a proven track record?

CHRISTOPHER MARAI

Which analyst has the most public recommendations on CTMX (CytomX Therapeutics)?

Christopher Marai has 8 price targets and 6 ratings on CTMX

Which analyst is the currently most bullish on CTMX (CytomX Therapeutics)?

Varun Kumar with highest potential upside - $21.71

Which analyst is the currently most reserved on CTMX (CytomX Therapeutics)?

Mara Goldstein with lowest potential downside - -$0.1

CytomX Therapeutics in the News

CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

– May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Antibody Drug Conjugate) in patients with advanced colorectal cancer (CRC) – – CX-2051 Phase 1 dose expansions on track for data update in Q1 2026. Phase 2 study initiation in CRC anticipated 1H 2026 – – Combination dose...

CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025

SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report second quarter financial results on Thursday, August 7, 2025, after the close of U.S. markets. Following the announcement, the Company will host a...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?